Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 6/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.49 |
| ▸ | GLS | O94925 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HEXA | P06865 | 1/20 | 0.47 |
| ▸ | HEXB | P07686 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26813895 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2GAAHPGDNPSR1RAB9A | |
| SCHEMBL26101354 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2GAAHPGDNPSR1RAB9A | |
| SCHEMBL30274282 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2GAAHPGDNPSR1RAB9A | |
| SCHEMBL30392446 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2GAAHPGDNPSR1RAB9A | |
| SCHEMBL30392640 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2GAAHPGDNPSR1RAB9A | |
| SCHEMBL3892107 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2GAAHPGDNPSR1RAB9A | |
| SCHEMBL23720311 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2GAAHPGDNPSR1RAB9A | |
| SCHEMBL19541802 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2GAAHPGDNPSR1RAB9A | |
| SCHEMBL230525 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2GAAHPGDNPSR1RAB9A | |
| SCHEMBL30274320 | 0.98 | SMN1; SMN2 (0.55) | SMN1; SMN2GAAHPGDNPSR1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0406502-B1 | Process for the preparation of (-)2-(2-(2-aminoethoxy)ethoxy)methyl)-4-(2, 3-dichlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine, and intermediate for its preparation | ADIR (FR) | 1995-05-10 | — | — | EP | claimed |
| US-4983740-A | Multistep; from 2- 2-/2-chloroethoxy/ethoxy!ethanol and potassium phthalimide | ADIR ET COMPAGNIE (FR) | 1991-01-08 | — | — | US | claimed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12528785-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12258341-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-01-02 | — | — | US | disclosed |
| US-20240424110-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-12-26 | — | — | US | disclosed |
| US-9932331-B2 | Phenyl tetrahydroisoquinoline compound substituted with heteroaryl | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2018-04-03 | — | — | US | disclosed |
| US-20170210736-A1 | PHENYL TETRAHYDROISOQUINOLINE COMPOUND SUBSTITUTED WITH HETEROARYL | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2017-07-27 | — | — | US | disclosed |
| EP-3173408-A1 | PHENYL TETRAHYDROISOQUINOLINE COMPOUND SUBSTITUTED WITH HETEROARYL | Taisho Pharmaceutical Co., Ltd. (JP) | 2017-05-31 | — | — | EP | disclosed |
| WO-2009060158-A1 | 4- (4-CYANOPHENYL) -1- (3-TRIFLUOROMETHYLPHENYL) -3,4, 6, 7-TETRAHYDRO-1H-PYRROLO [3, 4- D] PYRIMIDINE-2, 5-DIONE DERIVATIVES AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | ARGENTA DISCOVERY LIMITED (GB) | 2009-05-14 | — | — | WO | disclosed |
| US-7164014-B2 | Protected linker compounds | LINDEN TECHNOLOGIES, INC. (US) | 2007-01-16 | — | — | US | disclosed |
| US-20030105056-A1 | Protected linker compounds | LINDEN TECHNOLOGIES, INC. | 2003-06-05 | — | — | US | disclosed |
| WO-2003027314-A2 | PROTECTED LINKER COMPOUNDS | LINDEN TECHNOLOGIES, INC. (US) | 2003-04-03 | — | — | WO | disclosed |
| US-5026863-A | Medicinal products in racemic or enantiomorph form; calcium channel blockers. hypotensive agents, cardiovascular disorders | ADIR ET COMPAGNIE (FR) | 1991-06-25 | — | — | US | disclosed |
| US-4983740-A | Multistep; from 2- 2-/2-chloroethoxy/ethoxy!ethanol and potassium phthalimide | ADIR ET COMPAGNIE (FR) | 1991-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 2647/4885GAA 1234/4885HPGD 3843/4885 |
| US-12258341-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 2647/4885GAA 1234/4885HPGD 3843/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 2647/4885GAA 1234/4885HPGD 3843/4885 |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 2647/4885GAA 1234/4885HPGD 3843/4885 |
| US-20240424110-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, USP2, MYCBP2 | SMN1; SMN2 2413/4885GAA 1436/4885HPGD 3207/4885 |
| US-12528785-B2 | MDM2 degraders and uses thereof | MDM2, ADRM1, RBX1 | SMN1; SMN2 737/4885GAA 2635/4885HPGD 4011/4885 |
| US-20030105056-A1 | Protected linker compounds | NSUN2, MTAP, TYMP | SMN1; SMN2 469/4885GAA 2765/4885HPGD 4100/4885 |
| US-20170210736-A1 | PHENYL TETRAHYDROISOQUINOLINE COMPOUND SUBSTITUTED WITH HETEROARYL | NHERF1, SLC9A3, SLC26A3 | SMN1; SMN2 4511/4885GAA 2816/4885HPGD 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.